These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2715790)

  • 41. Effects of arginine vasopressin and oxytocin on glucagon release from clonal alpha-cell line In-R1-G9: involvement of V1b receptors.
    Yibchok-anun S; Hsu WH
    Life Sci; 1998; 63(21):1871-8. PubMed ID: 9825765
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prostaglandin synthesis by rat glomerular mesangial cells in culture. Effects of angiotensin II and arginine vasopressin.
    Scharschmidt LA; Dunn MJ
    J Clin Invest; 1983 Jun; 71(6):1756-64. PubMed ID: 6408123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vasopressin and oxytocin reduce plasma prolactin levels of conscious rats in basal and stress conditions. Study of the characteristics of the receptor involved.
    Mormede P; Vincent JD; Kerdelhue B
    Life Sci; 1986 Nov; 39(19):1737-43. PubMed ID: 3022094
    [TBL] [Abstract][Full Text] [Related]  

  • 44. V2-like vasopressin receptor mobilizes intracellular Ca2+ in rat medullary collecting tubules.
    Champigneulle A; Siga E; Vassent G; Imbert-Teboul M
    Am J Physiol; 1993 Jul; 265(1 Pt 2):F35-45. PubMed ID: 8342613
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Electrophysiological evidence for vasopressin V(1) receptors on neonatal motoneurons, premotor and other ventral horn neurons.
    Oz M; Kolaj M; Renaud LP
    J Neurophysiol; 2001 Sep; 86(3):1202-10. PubMed ID: 11535670
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Suppression of natriferic activity of the vasopressin molecule by modifications in positions 1, 2 and 4.
    Bakos P; Ponec J; Alexandrová M; Lichardus B; Lammek B; Rekowski P; Kupryszewski G
    Gen Physiol Biophys; 1990 Dec; 9(6):605-13. PubMed ID: 2079200
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),4-valine,-8-D-arginine]vasopressin, a potent and selective inhibitor of the vasopressor response to arginine-vasopressin.
    Lowbridge J; Manning M; Haldar J; Sawyer WH
    J Med Chem; 1978 Mar; 21(3):313-5. PubMed ID: 628009
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Arginine-vasopressin in nucleus of the tractus solitarius induces hyperglycemia and brain glucose retention.
    Yarkov A; Montero S; Lemus M; Roces de Alvarez-Buylla E; Alvarez-Buylla R
    Brain Res; 2001 Jun; 902(2):212-22. PubMed ID: 11384615
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mutual regulation of vasopressin- and oxytocin-induced glucagon secretion in V1b vasopressin receptor knockout mice.
    Fujiwara Y; Hiroyama M; Sanbe A; Yamauchi J; Tsujimoto G; Tanoue A
    J Endocrinol; 2007 Feb; 192(2):361-9. PubMed ID: 17283236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
    J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
    Manning M; Stoev S; Bankowski K; Misicka A; Lammek B; Wo NC; Sawyer WH
    J Med Chem; 1992 Jan; 35(2):382-8. PubMed ID: 1531076
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors-molecular dynamics study of the activated receptor-vasopressin-G(alpha) systems.
    Slusarz MJ; Giełdoń A; Slusarz R; Ciarkowski J
    J Pept Sci; 2006 Mar; 12(3):180-9. PubMed ID: 16114100
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biological activities of some new arginine vasopressin analogues containing unusual amino acids.
    Varga C; Somlai C; Baláspiri L; László FA
    Acta Physiol Hung; 1993; 81(2):183-92. PubMed ID: 8197874
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Arginine vasopressin inhibits interleukin-1 beta-stimulated nitric oxide and cyclic guanosine monophosphate production via the V1 receptor in cultured rat vascular smooth muscle cells.
    Kusano E; Tian S; Umino T; Tetsuka T; Ando Y; Asano Y
    J Hypertens; 1997 Jun; 15(6):627-32. PubMed ID: 9218182
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Some properties of the human platelet vasopressin receptor.
    Thomas ME; Osmani AH; Scrutton MC
    Thromb Res; 1983 Dec; 32(6):557-66. PubMed ID: 6320489
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Properties of [3H]1-desamino-8-D-arginine vasopressin as a radioligand for vasopressin V2-receptors in rat kidney.
    Marchingo AJ; Abrahams JM; Woodcock EA; Smith AI; Mendelsohn FA; Johnston CI
    Endocrinology; 1988 Apr; 122(4):1328-36. PubMed ID: 2964362
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design of potent antagonists of the vasopressor response to arginine-vasopressin.
    Bankowski K; Manning M; Haldar J; Sawyer WH
    J Med Chem; 1978 Sep; 21(9):850-3. PubMed ID: 722751
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.
    Griffante C; Green A; Curcuruto O; Haslam CP; Dickinson BA; Arban R
    Br J Pharmacol; 2005 Nov; 146(5):744-51. PubMed ID: 16158071
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.
    Manning M; Kruszynski M; Bankowski K; Olma A; Lammek B; Cheng LL; Klis WA; Seto J; Haldar J; Sawyer WH
    J Med Chem; 1989 Feb; 32(2):382-91. PubMed ID: 2913298
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular docking-based study of vasopressin analogues modified at positions 2 and 3 with N-methylphenylalanine: influence on receptor-bound conformations and interactions with vasopressin and oxytocin receptors.
    Slusarz MJ; Sikorska E; Slusarz R; Ciarkowski J
    J Med Chem; 2006 Apr; 49(8):2463-9. PubMed ID: 16610789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.